Literature DB >> 2373961

A cross-species comparison of the apolipoprotein B domain that binds to the LDL receptor.

A Law1, J Scott.   

Abstract

Apolipoprotein (apo)-B-100 is the ligand that mediates the clearance of low density lipoprotein (LDL) from the circulation by the apoB,E (LDL) receptor pathway. Clearance is mediated by the interaction of a domain enriched in basic amino acid residues on apoB-100 with clusters of acidic residues on the apoB,E (LDL) receptor. A model has been proposed for the LDL receptor binding domain of apoB-100 based on the primary amino acid sequence (Knott, T. J., et al. 1986. Nature. 323: 734-738). Two clusters of basic residues (A: 3147-3157 and B: 3359-3367) are apposed on the surface of the LDL particle by a disulfide bridge between Cys 3167 and 3297. Support for this single domain model has been obtained from the mapping of epitopes for anti-apoB monoclonal antibodies that block the binding of apoB to the LDL receptor. Here we test this model by comparing the nucleotide (from 9623 to 10,442) and amino acid sequence (from 3139 to 3411) of apoB-100 in seven species (human, pig, rabbit, rat, Syrian hamster, mouse, and chicken). Overall, this region is highly conserved. Cluster B maintains a strong net positive charge and is homologous across species in both primary and secondary structure. However, the net positive charge of region A is not conserved across these species, but the region remains strongly hydrophilic. The secondary structure of the region between clusters A and B is preserved, but the disulfide bond is unique to the human sequence. This study suggests that the basic region B is primarily involved in the binding of apoB-100 to the apoB,E (LDL) receptor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2373961

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  18 in total

1.  Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents.

Authors:  Gang Zheng; Juan Chen; Hui Li; Jerry D Glickson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-23       Impact factor: 11.205

2.  Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100.

Authors:  J Boren; I Lee; W Zhu; K Arnold; S Taylor; T L Innerarity
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

3.  Assembly of lipoprotein particles containing apolipoprotein-B: structural model for the nascent lipoprotein particle.

Authors:  Paul E Richardson; Medha Manchekar; Nassrin Dashti; Martin K Jones; Anne Beigneux; Stephen G Young; Stephen C Harvey; Jere P Segrest
Journal:  Biophys J       Date:  2005-01-14       Impact factor: 4.033

4.  Truncated apo B-70.5-containing lipoproteins bind to megalin but not the LDL receptor.

Authors:  Z Chen; J E Saffitz; M A Latour; G Schonfeld
Journal:  J Clin Invest       Date:  1999-05-15       Impact factor: 14.808

5.  Role of basic residues in the subgroup-determining region of the subgroup A avian sarcoma and leukosis virus envelope in receptor binding and infection.

Authors:  L Rong; A Edinger; P Bates
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

Review 6.  Recent advances in lipoprotein and atherosclerosis research at Baylor College of Medicine. Apolipoprotein B, lipoprotein[a], and transplantation arteriopathy.

Authors:  C M Ballantyne; L Chan; J Guevara; J D Morrisett; M P Mims; A M Gotto
Journal:  Tex Heart Inst J       Date:  1994

7.  Anti-infective activity of apolipoprotein domain derived peptides in vitro: identification of novel antimicrobial peptides related to apolipoprotein B with anti-HIV activity.

Authors:  Bridie A Kelly; Ian Harrison; Aine McKnight; Curtis B Dobson
Journal:  BMC Immunol       Date:  2010-03-18       Impact factor: 3.615

8.  Chemical composition-oriented receptor selectivity of L5, a naturally occurring atherogenic low-density lipoprotein.

Authors:  Liang-Yin Ke; David A Engler; Jonathan Lu; Risë K Matsunami; Hua-Chen Chan; Guei-Jane Wang; Chao-Yuh Yang; Jan-Gowth Chang; Chu-Huang Chen
Journal:  Pure Appl Chem       Date:  2011       Impact factor: 2.453

9.  Molecular structure of low density lipoprotein: current status and future challenges.

Authors:  Ruth Prassl; Peter Laggner
Journal:  Eur Biophys J       Date:  2008-09-17       Impact factor: 1.733

10.  Identification of a domain in apolipoprotein B-100 that inhibits the procoagulant activity of tissue factor.

Authors:  C Ettelaie; N J James; J M Adam; K P Nicola; B R Wilbourn; K R Bruckdorfer
Journal:  Biochem J       Date:  1998-07-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.